Jim Simons
MDGL icon

Jim Simons’s Madrigal Pharmaceuticals MDGL Stock Holding History

Jim Simons’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.6M Sell
71,870
-11,992
-14% -$5.73M 0.06% 412
2025
Q4 		$48.8M Sell
83,862
-36,820
-31% -$18.8M 0.08% 306
2025
Q3 		$55.4M Buy
120,682
+109,846
+1,014% +$41M 0.07% 317
2025
Q2 		$3.28M Sell
10,836
-74,250
-87% -$22.1M ﹤0.01% 1782
2025
Q1 		$28.2M Sell
85,086
-75,696
-47% -$24.9M 0.04% 523
2024
Q4 		$49.6M Buy
160,782
+116,285
+261% +$32.7M 0.07% 327
2024
Q3 		$9.44M Buy
+44,497
New +$11.4M 0.01% 1074
2023
Q4 		– Sell
-68,082
Closed -$9.94M – 3969
2023
Q3 		$9.94M Sell
68,082
-10,600
-13% -$2M 0.02% 922
2023
Q2 		$18.2M Sell
78,682
-96,700
-55% -$26.2M 0.03% 722
2023
Q1 		$42.5M Buy
175,382
+170,800
+3,728% +$46.5M 0.06% 396
2022
Q4 		$1.33M Buy
+4,582
New +$448K ﹤0.01% 2355
2022
Q2 		– Sell
-4,800
Closed -$471K – 4439
2022
Q1 		$471K Buy
4,800
+2,400
+100% +$202K ﹤0.01% 3234
2021
Q4 		$203K Sell
2,400
-14,711
-86% -$1.21M ﹤0.01% 3505
2021
Q3 		$1.36M Sell
17,111
-35,871
-68% -$3.1M ﹤0.01% 2376
2021
Q2 		$5.16M Buy
52,982
+18,700
+55% +$2.21M 0.01% 1614
2021
Q1 		$4.01M Buy
34,282
+249
+0.7% +$29K 0.01% 1794
2020
Q4 		$3.78M Buy
34,033
+12,251
+56% +$1.5M ﹤0.01% 1759
2020
Q3 		$2.59M Sell
21,782
-50,600
-70% -$5.49M ﹤0.01% 1979
2020
Q2 		$8.2M Buy
72,382
+45,900
+173% +$4.51M 0.01% 1343
2020
Q1 		$1.77M Buy
+26,482
New +$2.21M ﹤0.01% 2114
2018
Q1 		– Sell
-87,587
Closed -$8.04M – 3485
2017
Q4 		$8.04M Sell
87,587
-39,700
-31% -$2.27M 0.01% 1513
2017
Q3 		$5.72M Buy
127,287
+51,900
+69% +$971K 0.01% 1688
2017
Q2 		$1.23M Buy
75,387
+17,512
+30% +$274K ﹤0.01% 2496
2017
Q1 		$891K Buy
57,875
+400
+0.7% +$6.29K ﹤0.01% 2580
2016
Q4 		$856K Buy
57,475
+4,488
+8% +$72.1K ﹤0.01% 2607
2016
Q3 		$672K Sell
52,987
-3,187
-6% -$30.9K ﹤0.01% 2723
2016
Q2 		$512K Sell
56,174
-10,483
-16% -$126K ﹤0.01% 2791
2016
Q1 		$560K Sell
66,657
-4,892
-7% -$40.9K ﹤0.01% 2815
2015
Q4 		$881K Buy
+71,549
New +$1.96M ﹤0.01% 2519
2015
Q2 		– Sell
-18,763
Closed -$1.27M – 3303
2015
Q1 		$1.27M Buy
18,763
+489
+3% +$41.9K ﹤0.01% 2179
2014
Q4 		$1.7M Buy
18,274
+7,495
+70% +$775K ﹤0.01% 1890
2014
Q3 		$1.14M Buy
+10,779
New +$1.5M ﹤0.01% 1963
2014
Q1 		– Sell
-6,114
Closed -$1.12M – 2942
2013
Q4 		$1.12M Buy
+6,114
New +$1.12M ﹤0.01% 2022

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jim Simons's MDGL Position: Q1 2026 in Review

Jim Simons reduced its Madrigal Pharmaceuticals (MDGL) stake by 14% in Q1 2026, selling an estimated $5.73M and leaving 71,870 shares worth $37.6M. The position accounts for 0.06% of the portfolio, ranked #412.

Jim Simons first reported a position in MDGL in Q4 2013 and has held it in 33 quarters since. The position peaked at $55.4M in Q3 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Jim Simons held 71,870 shares of Madrigal Pharmaceuticals worth $37.6M as of Q1 2026.
  • Jim Simons sold 11,992 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $5.73M.
  • Madrigal Pharmaceuticals made up 0.06% of Jim Simons's portfolio in Q1 2026, its #412 holding.
  • Jim Simons first reported a position in Madrigal Pharmaceuticals in Q4 2013 and has held it in 33 quarters since.
  • Jim Simons's Madrigal Pharmaceuticals position peaked at $55.4M in Q3 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.